
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES142
The evidence appraised suggested that treatment with beta-blockers in patients with Type 2 diabetes failed to demonstrate a better CV profile when compared with CCB therapy. Furthermore a landmark RCT showed a significant reduction in the incidence of CV outcomes in patients receiving CCB as compared with those treated with beta-blockers. In terms of BP173 12 Blood pressure therapy * BP reduction with all hypertensive treatments was a consistent feature of the studies and therefore only studies where there were significant differences between the treatments will be highlighted. control, the evidence did not demonstrate differences between beta-blocker therapy and other antihypertensives.

[@Lindholm_2002]

[@Lewis_2001]

[@Zanchetti_2006]

[@Pepine_2004]

